Cystic Fibrosis (CF) is an inherited pleiotropic disease that results from abnormalities in the gene that codes for the chloride channel, Cystic Fibrosis Transmembrane Conductance Regulator (CFTR). CF patients are frequently colonized by several pathogens, but the mechanisms that allow colonization in spite of apparently functional immune systems are incompletely understood. In this paper we show that blood peripheral monocytes isolated from CF patients are found in an endotoxin tolerance state, yet this is not due to a deficient TLR activation. On the other hand, levels of the amplifier of inflammatory responses, TREM-1 (Triggering Receptor Expressed on Myeloid cells), are notably down-regulated in monocytes from patients, in comparison to those extracted from healthy volunteers. Furthermore, the soluble form of TREM-1 (sTREM-1) was not detected in the sera of patients. Additionally, and in strict contrast to patients who suffer from Chronic Obstructive Pulmonary Disease (COPD), CF monocytes challenged ex vivo with LPS neither up-regulated membrane-anchored TREM-1 nor sTREM-1. Finally, similar levels of PGE2 expression and p65 translocation into the nucleus were found in both patients and healthy volunteers, thus suggesting that TREM-1 regulation is neither controlled by PGE2 levels nor by p65 activation in this case. However, PU.1 translocation into the nucleus was significantly higher in CF monocytes than in controls, suggesting a role for this transcription factor in the control of TREM-1 expression. We conclude that down-regulation of TREM-1 expression in cystic fibrosis patients is at least partly responsible for the endotoxin tolerance state in which their monocytes are locked.
References
[1]
Rowe SM, Miller S, Sorscher EJ (2005) Cystic fibrosis. N Engl J Med 352: 1992–2001.
[2]
Gadsby DC, Vergani P, Csanady L (2006) The ABC protein turned chloride channel whose failure causes cystic fibrosis. Nature 440: 477–483.
[3]
Ratjen F, Doring G (2003) Cystic fibrosis. Lancet 361: 681–689.
Ramsey BW (1996) Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med 335: 179–188.
[6]
Bouchon A, Dietrich J, Colonna M (2000) Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol 164: 4991–4995.
[7]
Klesney-Tait J, Turnbull IR, Colonna M (2006) The TREM receptor family and signal integration. Nat Immunol 7: 1266–1273.
[8]
Knapp S, Gibot S, de Vos A, Versteeg HH, Colonna M, et al. (2004) Cutting edge: expression patterns of surface and soluble triggering receptor expressed on myeloid cells-1 in human endotoxemia. J Immunol 173: 7131–7134.
[9]
Gomez-Pina V, Soares-Schanoski A, Rodriguez-Rojas A, Del Fresno C, Garcia F, et al. (2007) Metalloproteinases shed TREM-1 ectodomain from lipopolysaccharide-stimulated human monocytes. J Immunol 179: 4065–4073.
[10]
Gibot S, Massin F, Marcou M, Taylor V, Stidwill R, et al. (2007) TREM-1 promotes survival during septic shock in mice. Eur J Immunol 37: 456–466.
Mohamadzadeh M, Coberley SS, Olinger GG, Kalina WV, Ruthel G, et al. (2006) Activation of triggering receptor expressed on myeloid cells-1 on human neutrophils by marburg and ebola viruses. J Virol 80: 7235–7244.
[13]
Murakami Y, Kohsaka H, Kitasato H, Akahoshi T (2007) Lipopolysaccharide-induced up-regulation of triggering receptor expressed on myeloid cells-1 expression on macrophages is regulated by endogenous prostaglandin E2. J Immunol 178: 1144–1150.
[14]
Tejera A, Santolaria F, Diez ML, Aleman-Valls MR, Gonzalez-Reimers E, et al. (2007) Prognosis of community acquired pneumonia (CAP): value of triggering receptor expressed on myeloid cells-1 (TREM-1) and other mediators of the inflammatory response. Cytokine 38: 117–123.
[15]
Gibot S, Cravoisy A, Kolopp-Sarda MN, Bene MC, Faure G, et al. (2005) Time-course of sTREM (soluble triggering receptor expressed on myeloid cells)-1, procalcitonin, and C-reactive protein plasma concentrations during sepsis. Crit Care Med 33: 792–796.
[16]
Gibot S, Kolopp-Sarda MN, Bene MC, Bollaert PE, Lozniewski A, et al. (2004) A soluble form of the triggering receptor expressed on myeloid cells-1 modulates the inflammatory response in murine sepsis. J Exp Med 200: 1419–1426.
[17]
Determann RM, Millo JL, Gibot S, Korevaar JC, Vroom MB, et al. (2005) Serial changes in soluble triggering receptor expressed on myeloid cells in the lung during development of ventilator-associated pneumonia. Intensive Care Med 31: 1495–1500.
[18]
Gibot S, Cravoisy A, Dupays R, Barraud D, Nace L, et al. (2007) Combined measurement of procalcitonin and soluble TREM-1 in the diagnosis of nosocomial sepsis. Scand J Infect Dis 39: 604–608.
[19]
Gibot S, Cravoisy A (2004) Soluble form of the triggering receptor expressed on myeloid cells-1 as a marker of microbial infection. Clin Med Res 2: 181–187.
[20]
Horonenko G, Hoyt JC, Robbins RA, Singarajah CU, Umar A, et al. (2007) Soluble triggering receptor expressed on myeloid cell-1 is increased in patients with ventilator-associated pneumonia: a preliminary report. Chest 132: 58–63.
[21]
Liu CL, Hsieh WY, Wu CL, Kuo HT, Lu YT (2007) Triggering receptor expressed on myeloid cells-1 in pleural effusions: a marker of inflammatory disease. Respir Med 101: 903–909.
[22]
How CK, Chern CH, Wu MF, Wang LM, Huang CI, et al. (2007) Expression of the triggering receptor expressed on myeloid cells-1 mRNA in a heterogeneous infected population. Int J Clin Pract.
[23]
Rosenstein BJ, Cutting GR (1998) The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. J Pediatr 132: 589–595.
[24]
Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS (2001) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 163: 1256–1276.
[25]
Mahler DA, Wells CK (1988) Evaluation of clinical methods for rating dyspnea. Chest 93: 580–586.
[26]
Celli BR, MacNee W (2004) Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 23: 932–946.
[27]
Escoll P, del Fresno C, Garcia L, Valles G, Lendinez MJ, et al. (2003) Rapid up-regulation of IRAK-M expression following a second endotoxin challenge in human monocytes and in monocytes isolated from septic patients. Biochem Biophys Res Commun 311: 465–472.
[28]
del Fresno C, Otero K, Gomez-Garcia L, Gonzalez-Leon MC, Soler-Ranger L, et al. (2005) Tumor cells deactivate human monocytes by up-regulating IL-1 receptor associated kinase-M expression via CD44 and TLR4. J Immunol 174: 3032–3040.
[29]
Lopez-Collazo E, Hortelano S, Rojas A, Bosca L (1998) Triggering of peritoneal macrophages with IFN-alpha/beta attenuates the expression of inducible nitric oxide synthase through a decrease in NF-kappaB activation. J Immunol 160: 2889–2895.
[30]
Govan JR, Brown AR, Jones AM (2007) Evolving epidemiology of Pseudomonas aeruginosa and the Burkholderia cepacia complex in cystic fibrosis lung infection. Future Microbiol 2: 153–164.
[31]
Saiman L, Siegel J (2004) Infection control in cystic fibrosis. Clin Microbiol Rev 17: 57–71.
[32]
Kim HM, Park BS, Kim JI, Kim SE, Lee J, et al. (2007) Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell 130: 906–917.
[33]
del Fresno C, Soler-Rangel L, Soares-Schanoski A, Gomez-Pina V, Gonzalez-Leon MC, et al. (2007) Inflammatory responses associated with acute coronary syndrome up-regulate IRAK-M and induce endotoxin tolerance in circulating monocytes. J Endotoxin Res 13: 39–52.
[34]
Kobayashi K, Hernandez LD, Galan JE, Janeway CA Jr, Medzhitov R, et al. (2002) IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 110: 191–202.
[35]
Lopez-Collazo E, Fuentes-Prior P, Arnalich F, del Fresno C (2006) Pathophysiology of interleukin-1 receptor-associated kinase-M: implications in refractory state. Curr Opin Infect Dis 19: 237–244.
[36]
Gibot S, Cravoisy A, Levy B, Bene MC, Faure G, et al. (2004) Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. N Engl J Med 350: 451–458.
[37]
Richeldi L, Mariani M, Losi M, Maselli F, Corbetta L, et al. (2004) Triggering receptor expressed on myeloid cells: role in the diagnosis of lung infections. Eur Respir J 24: 247–250.
[38]
Gibot S, Alauzet C, Massin F, Sennoune N, Faure GC, et al. (2006) Modulation of the triggering receptor expressed on myeloid cells-1 pathway during pneumonia in rats. J Infect Dis 194: 975–983.
[39]
Gibot S (2006) The therapeutic potential of TREM-1 modulation in the treatment of sepsis and beyond. Curr Opin Investig Drugs 7: 438–442.
[40]
Zeng H, Ornatowska M, Joo MS, Sadikot RT (2007) TREM-1 expression in macrophages is regulated at transcriptional level by NF-kappaB and PU.1. Eur J Immunol 37: 2300–2308.
[41]
DeKoter RP, Kamath MB, Houston IB (2007) Analysis of concentration-dependent functions of PU.1 in hematopoiesis using mouse models. Blood Cells Mol Dis 39: 316–320.
[42]
Norman D, Elborn JS, Cordon SM, Rayner RJ, Wiseman MS, et al. (1991) Plasma tumour necrosis factor alpha in cystic fibrosis. Thorax 46: 91–95.
[43]
Elborn JS, Norman D, Delamere FM, Shale DJ (1992) In vitro tumor necrosis factor-alpha secretion by monocytes from patients with cystic fibrosis. Am J Respir Cell Mol Biol 6: 207–211.
[44]
Jaresova I, Rozkova D, Spisek R, Janda A, Brazova J, et al. (2007) Kinetics of Toll-like receptor-4 splice variants expression in lipopolysaccharide-stimulated antigen presenting cells of healthy donors and patients with cystic fibrosis. Microbes Infect 9: 1359–1367.
[45]
Massengale AR, Quinn F Jr, Yankaskas J, Weissman D, McClellan WT, et al. (1999) Reduced interleukin-8 production by cystic fibrosis airway epithelial cells. Am J Respir Cell Mol Biol 20: 1073–1080.
[46]
Hartl D, Latzin P, Hordijk P, Marcos V, Rudolph C, et al. (2007) Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease. Nat Med 13: 1423–1430.
[47]
Muir A, Soong G, Sokol S, Reddy B, Gomez MI, et al. (2004) Toll-like receptors in normal and cystic fibrosis airway epithelial cells. Am J Respir Cell Mol Biol 30: 777–783.
[48]
Dehus O, Hartung T, Hermann C (2006) Endotoxin evaluation of eleven lipopolysaccharides by whole blood assay does not always correlate with Limulus amebocyte lysate assay. J Endotoxin Res 12: 171–180.
[49]
Radsak MP, Taube C, Haselmayer P, Tenzer S, Salih HR, et al. (2007) Soluble triggering receptor expressed on myeloid cells 1 is released in patients with stable chronic obstructive pulmonary disease. Clin Dev Immunol 2007: 52040.
[50]
Xu Y, Clark JC, Aronow BJ, Dey CR, Liu C, et al. (2003) Transcriptional adaptation to cystic fibrosis transmembrane conductance regulator deficiency. J Biol Chem 278: 7674–7682.
[51]
Dorin JR, Novak M, Hill RE, Brock DJ, Secher DS, et al. (1987) A clue to the basic defect in cystic fibrosis from cloning the CF antigen gene. Nature 326: 614–617.
[52]
Wilkinson MM, Busuttil A, Hayward C, Brock DJ, Dorin JR, et al. (1988) Expression pattern of two related cystic fibrosis-associated calcium-binding proteins in normal and abnormal tissues. J Cell Sci 91 (Pt 2): 221–230.
[53]
Yang Z, Wara-Aswapati N, Chen C, Tsukada J, Auron PE (2000) NF-IL6 (C/EBPbeta ) vigorously activates il1b gene expression via a Spi-1 (PU.1) protein-protein tether. J Biol Chem 275: 21272–21277.
[54]
Mouri F, Tsukada J, Mizobe T, Higashi T, Yoshida Y, et al. (2008) Intracellular HMGB1 transactivates the human IL1B gene promoter through association with an Ets transcription factor PU.1. Eur J Haematol 80: 10–19.
[55]
Lichanska AM, Browne CM, Henkel GW, Murphy KM, Ostrowski MC, et al. (1999) Differentiation of the mononuclear phagocyte system during mouse embryogenesis: the role of transcription factor PU.1. Blood 94: 127–138.
[56]
Henkel GW, McKercher SR, Maki RA (2002) Identification of three genes up-regulated in PU.1 rescued monocytic precursor cells. Int Immunol 14: 723–732.
[57]
Xu Y, Liu C, Clark JC, Whitsett JA (2006) Functional genomic responses to cystic fibrosis transmembrane conductance regulator (CFTR) and CFTR(delta508) in the lung. J Biol Chem 281: 11279–11291.
[58]
Hoefnagel JJ, Mulder MM, Dreef E, Jansen PM, Pals ST, et al. (2006) Expression of B-cell transcription factors in primary cutaneous B-cell lymphoma. Mod Pathol 19: 1270–1276.
[59]
Schoni MH, Schoni-Affolter F, Jeffery D, Katz S (1987) Intracellular free calcium levels in mononuclear cells of patients with cystic fibrosis and normal controls. Cell Calcium 8: 53–63.
